A carregar...
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
OBJECTIVE: Janus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, potentially related to differential JAK family member selectivity. Filgotinib was compared with baricitinib, tofacitinib and upadacitinib to elucidate the pharma...
Na minha lista:
| Publicado no: | Ann Rheum Dis |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8237188/ https://ncbi.nlm.nih.gov/pubmed/33741556 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2020-219012 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|